Allena Bets On Its Kidney Stone Treatment Despite Placebo Concerns

11 Nov 2019

• By Leah Samuel

Execs are hoping having positive results in two studies will help raise funds for continued development. But high placebo results have caused concern for investors.

Human kidney on scientific background. 3d illustration — Reloxliase lowers oxalate in the kidneys, thus preventing kidney stones

Allena Pharmaceuticals Inc.’s reloxaliase reduced kidney stone formation in two patient populations. But unexpectedly high placebo results from one trial could hamper the small biotech firm in securing financing for further studies.

“Taken together, we believe the results presented today highlight the opportunity for reloxaliase to favorably impact patients across the disease spectrum,” CEO Louis Brenner told a 7 November investor call announcing the results of its first Phase III trial, URIROX-1, as well as Study 206, a Phase II trial in EH patients with chronic kidney disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

06 May 2025

• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.